FLC
BIOS

Fifth Lane Capital’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Fifth Lane Capital’s Portfolio BIOS Stock Details BIOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-102,500
Closed -$1.01M – 457
2022
Q1 		$1.01M Buy
+102,500
New +$1.01M 0.62% 43

Other funds holding BIOS

SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

Fifth Lane Capital's BIOS Position: Q2 2022 in Review

Fifth Lane Capital sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q2 2022, closing a stake of 102,500 shares — an estimated $1.01M sold.

Fifth Lane Capital first reported a position in BIOS in Q1 2022 and held it in 1 quarter. The position peaked at $1.01M in Q1 2022. 65 funds tracked by Wall St. Rank hold BIOS as of Q2 2022.

  • Fifth Lane Capital reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q2 2022 after selling out during the quarter.
  • Fifth Lane Capital sold 102,500 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q2 2022, an estimated $1.01M.
  • Fifth Lane Capital first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 1 quarter.
  • Fifth Lane Capital's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $1.01M in Q1 2022.
  • 65 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q2 2022.

Based on Fifth Lane Capital's 13F filing for Q2 2022, filed 15 Aug 2022.